Graft vs. Host Disease and Graft vs. Myeloma Effect after Non-myeloablative Allogeneic Transplantation

References

• Gregory, W.M., Richards, M.A. and Malpas, J.S. (1992) "Combi-nation chemotherapy versus melphalan plus predisolone as the treatment of multiple myeloma: an overview of published trials", J. Clin. Oncol., 10(2), 334.
   Google Scholar
• Myeloma Tryalists' Collaborative Group (1998) "Combination chemotherapy versus melphalan plus prednisolone as treatment of multiple myeloma: an overview of 6633 patients from 27 rando-mized trials", J. Clin. Oncol., 16(12), 3832.
   Google Scholar
• Blade, J., San Miguel, J.F., Fontanillas, M., et al. (2001) "Increased conventional chemotherapy does not improbe survival in multiple myeloma: long term results of two trials including 914 patients", Hematol. J., 2, 272–278.
   Google Scholar
• Richardson, P., Barlogie, B., Berenson, J., et al. (2003) "A phase 2 study of Bortezomid in relapsed, refractory myeloma", N. Engl. J. Med., 348, 2609 — 2617.
   Google Scholar
• Garcia-Sauz, R., Gonzalez-Pruas, J.R. and Hernainder, J.M. (2004) "The oral combination of thalidomide, cyclophosphamide oxide dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma", Leukemia, 18, 856–863.
   Google Scholar
• Attal, M., Harousseau, J.L., Stoppa, A., et al. (1996) "A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma", N. Engl. J. Med., 335, 91–97.
   Google Scholar
• Child, J.A., Morgan, G.J., Davies, F.E., et al. (2003) "High dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma", N. Engl. J. Med., 348, 1875 — 1883.
   Google Scholar
• Powles, R., Sirohi, B., Treveleaven, J., et al. (2000) "Continued first complete remission in multiple myeloma for over 10 years: a series of operationally cured patients", Blood, 96, 515.
   Google Scholar
• Fermand, J.P., Ravaud, P., Chevret, S., et al. (1998) "High dose therapy and autologous peripheral stem cell transplantation in multiple myeloma: up front or rescue treatment? Results of a sequential randomized clinical trial", Blood, 92, 3131–3136.
   Google Scholar
• Fermand, J., Ravaud, P., Katsahian, S., et al. (1999) "High dose chemotherapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55 to 65 years of age", Blood, 94, abstr 1754.
   Google Scholar
• Blade, J., Sureda, A., Ribera, J.M., et al. (2001) "High dose therapy and autotransplantation/intensification vs. continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy: results of a prospective randomized trial from the Spanish Cooperative Group PETHEMA", Blood, 98, abstr 815.
   Google Scholar
• Alexanian, R., Dimmopoulos, M.A., Hester, J., et al. (1994) "Early myeloablative therapy for multiple myeloma", Blood, 84, 4278 — 4282.
   Google Scholar
• Blade, J., San Miguel, J., Fontanillas, M., et al. (1996) "Survival of multiple myeloma patients who are potential candidates for early high dose therapy intensification/autotransplantation and who were conventionally treated", J. Clin. °flea, 14, 2167 — 2173.
   Google Scholar
• Alexanian, R., Weber, D., Giralt, S., et al. (2001) "Impact of complete remission with intensive therapy in patients with responsive multiple myeloma", Bone Marrow Transplant., 27, 1037 — 1043.
   Google Scholar
• Barlogie, B., Jagannath, S., Vesole, D.H., et al. (1997) "Superiority of tandem autologus transplantation over standard therapy for previously untreated multiple myeloma", Blood, 89, 789–793.
   Google Scholar
• Barlogie, B., Jagannath, S., Desikan, KR., et al. (1999) "Total therapy with tandem transplants for newly diagnosed multiple myeloma", Blood, 93, 55–65.
   Google Scholar
• Lahuerta, ii., Grande, C., Martinez-Lopez, J., et al. (2003) "Tandem transplant with different high-dose regimens improbé the complete remission rate in multiple myeloma: results of the GEL/TAMO", Br. J. Hematol., 120(2), 296–303.
   Google Scholar
• Attal, M., Harouseau, J.L., Facon, T., et al. (2003) "Single versus double autologous stem cell transplantation for multiple myeloma", N. Engl. J. Med., 349, 2495–2502.
   Google Scholar
• Reynolds, C., Ratanatharathorn, V., Adams, P., et al. (2001) "Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma", Bone Marrow Transplant., 27, 801 —807.
   Google Scholar
• Cavo, M., Terragna, C., Martinelli, G., Ronconi, S., Zamagni, E., Tosi, P., et al. (2000) "Molecular monitoring of minimal residual disease in patients in long term complete remission after allogeneic stem cell transplantation for multiple myeloma", Blood, 96, 355 — 357.
   Google Scholar
• Martinelli, G., Terragna, C., Zamagni, E., Ronconi, S., Tosi, P., Lemoli, R.M., et al. (2000) "Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma", J. Clin. °flea, 18, 2273–2281.
   Google Scholar
• Bensinger, W., Buckner, CD., Anasetti, C., Clift, R., Storb, R., Barnett, T., et al. (1996) "Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome", Blood, 88(7), 2787 — 2793.
   Google Scholar
• Gahrton, G., Tura, S., Ljungman, P., Belanger, C., Brandt, L., Cavo, M., etal. (1991) "Allogeneic bone marrow transplantation in multiple myeloma: European Group for Bone Marrow Transplan-tation", N. Engl. J. Med., 325, 1267 — 1273.
   Google Scholar
• Gahrton, G., Tura, S., Ljungman, P., et al. (1995) "Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma", J. Clin. °flea, 13(6), 1312— 1322.
   Google Scholar
• Gahrton, G., Svensson, H., Cavo, M., et al. (2001) "Progress in allogenic bone marrow and peripheral blood stem cell transplan-tation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres", Br. J. Haematol., 113, 209— 216.
   Google Scholar
• Björkstrand, B.B., Ljungman, P., Svensson, H., et al. (1996) "Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation", Blood, 88, 4711 — 4718.
   Google Scholar
• Alyea, E., Weller, E., Schlossman, R., Canning, C., Mauch, P., Ng, A., et al. (2003) "Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft versus myeloma effect", Bone Marrow Transplant., 32, 1145 — 1151.
   Google Scholar
• Schiller, G., Vescio, R., Freytes, C., et al. (1995) "Transplantation of CD34 + peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma", Blood, 86, 390 — 397.
   Google Scholar
• Stewart, AK., Vescio, R., Schiller, G., et al. (2001) "Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression free survival after high dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial", J. Clin. Oncol., 19, 3771 — 3779.
   Google Scholar
• Or, R., Mehta, J., Naparstek, E., et al. (1992) "Successful T cell-depleted allogeneic bone marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas", Bone Marrow Transplant., 10, 381 — 382.
   Google Scholar
• Tricot, G., Vesole, D., Jagannath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996) "Graft versus myeloma effect: proof of principle", Blood, 87(3), 1196 — 1198.
   Google Scholar
• Verdonck, L.F., Lokhorst, H.M., Dekker, A.W., et al. (1996) "Graft versus myeloma effect in two cases", Lancet, 347, 800–801.
   Google Scholar
• Metha, J., Singhal, S. (1998) "Graft-versus-myeloma", Bone Marrow Transplant., 22, 835–843.
   Google Scholar
• Lokhorst, H.M., Schattenberg, A., Cornelissen, ii., Thomas, L.L.M. and Verdonk, L.F. (1997) "Donor Leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation", Blood, 90(10), 4206–4211.
   Google Scholar
• Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., van Oers, M.H., Fibbe, W., Russell, I., et al. (2000) "Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem cell transplantation: predictive factors for response and long term outcome", J. Clin. Oncol., 18(16), 3031 — 3037.
   Google Scholar
• Bertz, H., Burger, J.A., Kunzmann, R., et al. (1997) "Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft versus myeloma effect", Leukemia, 11, 28 1— 283.
   Google Scholar
• Alyea, E., Weller, E., Schlossman, R., Canning, C., Webb, I., Doss, D., et al. (2001) "T cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft versus myeloma effect", Blood, 98(4), 934–939.
   Google Scholar
• Libura, J., Hoffman, T., Passweg, J.R., Gregor, M., Favre, G., Tichelli, A., et al. (1999) "Graft versus myeloma after withdrawal of immunosuppresion following allogeneic peripheral stem cell trans-plantation", Bone Marrow Transplant., 24, 925–927.
   Google Scholar
• Voena, C., Maltani, M., Majolino, I., Fagd, G., Montefusco, V., Farina, L., et al. (2003) "Detection of minimal residual disease by real time PCR can be used as a surrogate marker to evaluate the graft versus myeloma effect after allogeneic stem cell transplanta-tion", Bone Marrow Transplant., 32, 791 — 793.
   Google Scholar
• Giralt, S., Aleman, A., Anagnostopoulos, A., Weber, D., Khouri, I., Anderlini, P., et al. (2002) "Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma", Bone Marrow Transplant., 30, 367–373.
   Google Scholar
• Badros, A., Barlogie, B., Morris, C., Desikan, R., Martin, S., Munshi, N., et al. (2001) "High response rate in refractory and poor risk multiple myeloma after allotransplantation using a nonmyeloa-blative conditioning regimen and donor lymphocyte infusions", Blood, 97(9), 2574–2579.
   Google Scholar
• Badros, A., Barlogie, B., Siegel, E., Cottler-Fox, M., Zangari, M., Fassas, A., et al. (2002) "Improved outcome of allogeneic transplantation in high risk multiple myeloma patients after non myeloablative conditioning", J. Clin. Oncol., 20(5), 1295–1303.
   Google Scholar
• Desikan, R., Barlogie, B., Swayer, J., et al. (2000) "Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities", Blood, 95, 4008 — 4010.
   Google Scholar
• Perez-Simon, J.A., Garcia-Sanz, R., Tabernero, M.D., et al. (1998) "Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes", Blood, 91(9), 3366 — 3371.
   Google Scholar
• Perez-Simon, J.A., Martino, R., Alegre, A., Tomas, J.F., De Leon, A., Caballero, D., et al. (2003) "Chronic but not acute Graft versus host disease improves outcome in multiple myeloma patients after nonmyeloablative allogeneic transplantation", Br. J. Hematol., 121, 104 — 108.
   Google Scholar
• Einsele, H., Schafer, H., Hebart, H., Bader, P., Meisner, C., Plasswilm, L., et al. (2003) "Follow up of patients with progressive multiple myeloma undergoing allografts after reduced intensity conditioning", Br. J. Hematol., 121, 411–418.
   Google Scholar
• Kroger, N., Schwerdtfeger, R., Kiehl, M., Sayer, HG., Renges, H., Zabelina, T., et al. (2002) "Autologous stem cell transplantation followed by a dose reduced allograft induces high complete remission rate in multiple myeloma", Blood, 100(3), 755–760.
   Google Scholar
• Kroger, N., Sayer, HG., Schwerdtfeger, R., Kiehl, M., Nagler, A., Renges, H., et al. (2002) "Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation related mortality", Blood, 100(12), 3919 — 3924.
   Google Scholar
• Maloney, D., Molina, A., Sahebi, F., Stocherl-Goldstein, E., Sandmaier, B., Bensinguer, W., et al. (2003) "Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma", Blood, 102(9), 3447 — 3454.
   Google Scholar
• Kroger, N., Pörez-Simón, J.A., Myint, H., et al. (2003) "Influence of tyming allogeneic stem cell transplantation after dose reduced melphalan/fludarabine conditioning in multiple myeloma", Blood, 102(11), abstract 2694.
   Google Scholar
• Kroger, N., Scilling, G., Einsele, H., et al. (2004) "Deletion of chromosome 13q14 detected by fluorescence in situ hybridization as prognostic factor following allogeneic dose reduced stem cell transplantation in patients with multiple myeloma", Blood, (in press).
   Google Scholar
• Facon, T., Avet-Loiseau, H., Guillerm, G., et al. (2001) "Intergrupe Francophone du Myeloma. Chromosome 13 abnormalities identi-fied by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high dose therapy", Blood, 97, 1566— 1571.
   Google Scholar
• Luft, T., Moos, M., Goldschmidt, H., Ho, A. and Gömer, M. (2003) "Dissociation of putative graft versus hematopoiesis and graft versus myeloma effects in patients with rapidly progressive multiple myeloma", Br. J. Hematol., 123, 646–653.
   Google Scholar
• Gorschliiter, M., Ziske, C., Glasmacher, A. and Schmidt-Wolf, I. (2001) "Current Clinical and Laboratory strategies to augment the efficacy on immunotherapy in multiple myeloma", Clin. Cancer Res., 7, 2195–2204.
   Google Scholar
• Belluci, R., Wu, C., Chiaretti, S., et al. (2004) "Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens", Blood, 103, 656 — 663.
   Google Scholar
• Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., et al. (1999) "Idiotype vaccination in Human Myeloma: generation of tumor-specific immune responses after high dose chemotherapy", Blood, 94(2), 673–683.
   Google Scholar
• Wen, Y., Barlogie, B., Yi, Q., et al. (2001) "Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells", Blood, 7, 1750–1755.
   Google Scholar
• Rasmussen, T., Hansson, L., Osterborg, A., Johnsen, H. and Mellstedt, H. (2003) "Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells", Blood, 101(1), 4607–4610.
   Google Scholar
• Hayashi, T., Hideshima, T., Akiyama, M., Raje, N., Richardson, P., Chauhan, D., et al. (2003) "Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes", Blood, 102(4), 1435 — 1442.
   Google Scholar
• Milazzo, C., Reichardt, V., Milner, M., Griinebach, F. and Brossart, P. (2003) "Induction of myeloma specific cytotoxic T cells using dendritic cells transfected with tumor derived RNA", Blood, 101(3), 977 — 982.
   Google Scholar